

MARYLAND LIFE SCIENCES
ADVISORY BOARD

ANNUAL STATUS REPORT
Fiscal Year 2013

Economic Development Article, Section 3-205

Submitted by the

Maryland Department of Business and Economic Development

December 2013

Table of Contents

Introduction	3
LSAB Background	3
Summary of FY 2013 Activities	4
Increasing Access to Capital	6
Ensuring Industry Growth and Competitiveness	9
Advancing Global BioMaryland/Branding	10
BioMaryland 2020 –Implementation	11
Summary	11
Appendices	
A. Life Sciences Advisory Board Composition	12
B. Maryland’s Life Science Jobs	13
C. Bio 2020 Strategic Plan Funding	14

Introduction

Pursuant to § 3–205 of the Maryland Economic Development Article, The Maryland Life Sciences Advisory Board (LSAB) presents the following report to the Governor and, in accordance with § 2–1246 of the State Government Article, to the General Assembly. The report includes a summary of the activities and recommendations of the LSAB during FY 2013.

The LSAB used *BioMaryland 2020: A Strategic Plan for the Life Sciences in Maryland* (published in 2009), as a roadmap for maximizing Maryland’s unique life sciences research and development assets. This plan was the outgrowth of a commitment by Governor Martin O’Malley in 2007 to invest \$1.3 billion over the next 10 years in the life sciences industry.

Including the federal, academic and private industry sectors, the life sciences sector directly accounts for 71,600 jobs, or 3% of all jobs in Maryland, at an average annual salary of \$91,100 (*see Appendix B*). Maryland has over 1,700 private sector establishments directly involved in life sciences work, and 6% of Maryland’s Gross Domestic Product is generated by the life sciences. More than 160,000 jobs in the State are directly and indirectly related to life sciences, according to *Life Sciences Maryland: Jobs Analysis and Economic Impact Report 2011*, generating \$9.6 billion in salaries and providing \$500 million in income and sales tax support annually to the State. One-third of Maryland’s job gains during 2002-2010 were in the life sciences sector.

Life Sciences Advisory Board Background

Governor Martin O’Malley signed into law the creation of the LSAB on May 9, 2007, to assist in maintaining the preeminence of Maryland’s life sciences industry. On September 18, 2007, the Governor formally introduced the LSAB’s 15 original members at a ceremony held in Annapolis. According to § 3–205 of the Maryland Economic Development Article, the Life Sciences Advisory Board was established to assist the Department in:

- Developing a comprehensive State strategic plan for life sciences;
- Making recommendations to address critical needs in the life sciences, including access to venture capital;
- Developing a strategy to attract private sector investment and job creation in the life sciences;
- Promoting life sciences research, development, commercialization, and manufacturing in the State;

- Promoting collaboration and coordination among industry, academia, and government including private research institutions of higher education in the State; and
- Supporting federal life sciences facilities located in the State to facilitate collaboration with other life sciences organizations.

Board Membership

The LSAB's membership includes the Secretary of the Maryland Department of Business and Economic Development (DBED), a representative designated by the Maryland Technology Development Corporation (TEDCO), and 13 members appointed by the Governor. The 13 appointees include representatives from the following groups located in the State:

- (i) three federal agencies with life sciences missions;
- (ii) four individuals with executive experience in life sciences businesses ;
- (iii) four representing institutions of higher education, one of whom shall represent a community college;
- (iv) one with general business marketing experience in a life sciences business; and
- (v) one member of the general public.

The 2012 Maryland General Assembly, via chapters 498 and 499, created three additional positions for the LSAB, bringing its membership to a total of 18. These three additional members, whose appointments were finalized in early FY 2014 represent life science companies.

See Appendix A for a list of LSAB members.

Summary of FY 2013 Activities

The LSAB has engaged Maryland's bioscience community in a continuing dialogue about future directions for the State's life science industry. In FY 2013, the LSAB held three meetings. All meeting agendas, presentations, minutes, and public comments can be found on the LSAB website: www.Bio.Maryland.gov

September 25, 2012

University of Maryland BioPark
801 W. Baltimore Street
Baltimore, MD

FY 2013's first meeting was held at the University of Maryland BioPark in September 2012. This meeting commenced the year's focus on metrics, measurements, and a discussion regarding how to measure achievements toward the BioMaryland 2020 as the midpoint of this plan is approached. Nancy McCrea, DBED's Director of Research and Information Services, introduced the Life Sciences Maryland: Job Analysis and Economic Impact Report produced by her office. *Highlights of this report are included in Appendix B.* The BioMaryland Center's BioEntrepreneur Development Awards presentations also took place. Presentations were made by four of the previous award recipients:

- Eddy Agbo, President, Fyodor Biotechnologies, Inc. -- BioCommercialization Award, 2010 to develop a quick inexpensive point of care test to detect malaria in urine.
- David Block, President, Gliknik – Translational Research Award, 2010—to further develop transplant drug therapy
- Brennan Klose, Executive Director, Unither Virology – Translational Research Award, 2011--to develop broad spectrum of antivirals to be used as universal treatment (e.g. for HIV, flu and dengue)
- Ted Olsen, President, PathSensors, Inc. – BioCommercialization Award, 2012—to develop a better test for bacterial detection (*Campylobacter pylori*) in food

January 17, 2013

Pharmathene, Inc.
One Park Place, Suite 450
Annapolis, MD

The second meeting was held in January 2013 at Pharmathene in Annapolis. Eric Richman, President of Pharmathene, introduced Pharmathene's achievements in the field of biodefense, one of the unique assets in Maryland's life science sector. The BioMaryland Center led discussion on measuring the impact of investment in the life sciences included additional data and potential metrics. The FDA and University of Maryland have partnered to create the Center for Excellence in Regulatory Science (CERSI), a pioneering program introduced by Drs. James Polli (Presenter) and Bill Bentley, Co-Directors. This program is a collaborative effort between UMCP and UMB's School of Pharmacy. Tom Dann, Managing Director of the Maryland Venture Fund, discussed InvestMaryland, and the creative mechanism for raising this fund, the largest venture capital investment in the State's history. The first investment was Brainscope, a life science company. The InvestMaryland Challenge was also discussed, the first Statewide business plan competition, a way to increase the visibility of the fund nationally and grow the investment pipeline.

June 4, 2013

House of Delegates Office Building
6 Bladen Street
Annapolis, MD

The third meeting was held in June 2013 at the Maryland House of Delegates Building in Annapolis. At this meeting, the BioMaryland Center's accomplishments were reviewed in preparation for the BioMaryland 2020 midpoint analysis, and the Board discussed obtaining a third party report on the economic impact of the State's investment in Life Sciences. The LSAB reviewed highlights of the 2013 Maryland General Assembly Session. The LSAB was involved in providing testimony on behalf of funding for Maryland programs important to the bioscience community. During FY 2013, the Biotechnology Investment Incentive Tax Credit (BIITC) was increased from \$8 to \$10 million and the Research and Development (R&D) Tax Credit was increased from \$6 million to \$8 million.

The 2013 BioEntrepreneur Development Awards recipients were introduced, and presentations made by the following 2013 recipients:

- Adlyfe – Richard Cliff, Chief Operating Officer/Chief Financial Officer – Translational Research Award, 2013, to *advance the development of a proprietary minimally invasive ocular imaging test for the early detection of Alzheimer’s.*
- Animalgesic Labs – David Allen, CEO – BioCommercialization Award, 2013, to *build out marketing infrastructure, and manufacture first commercial batch of product to manage pain associated with experimental treatments in rodents.*
- CardioSolv Ablation Technologies – Robert Blake, Head of Software Development – Translational Research Award, 2013, to *undertake prospective human validation study predicting non-invasively the optimal ablation targets for ventricular tachycardia patients.*
- Remedium Technologies, Inc. – Matt Dowling, CEO – Translational Research Award, 2013, to *validate a novel sprayable foam hemostat Hemogrip™ (and its reversibility), in a study on non-compressible bleeds in large animals.*

MAJOR OBJECTIVES


The major areas of focus for the LSAB in FY 2013 were in line with the major goals of the strategic plan:

- Increasing Access to Capital
- Ensuring Industry Growth and Competitiveness
- Advancing Global Leadership
- Increasing Visibility of BioMaryland Branding

One of the responsibilities of the Board is to monitor the activity against these key goals as laid out in the BioMaryland Strategic Plan and make recommendations moving forward. In that capacity, each of the major State programs is reviewed on a regular basis.

I. Increasing Access to Capital

A key priority of the *BioMaryland 2020* Strategic Plan is to increase access to capital. Since FY 2010, the cumulative investment in Maryland’s life sciences has totaled approximately \$600 million, with about half of that spent on programs and half on infrastructure. This is compared with Massachusetts, which has spent just \$400 million over the same period.



For details, please refer to the spreadsheet in Appendix C

In general, the Board has recommended a balanced and more strategic approach to the State's budget and has supported increases in funding to highly effective programs (e.g., BIITC) while recognizing that most programs are likely to remain flat-funded.

The BioMaryland Center Entrepreneurial Development Award Program

The BioMaryland Center (BMC) executed the third year of its competitive award program to companies developing and commercializing new products and services. To date, \$6 million dollars have been disbursed to 27 companies under this program. In FY2013, seventy applications were received and seven awards were made, totaling \$1.4 million. These awards, which have a maximum of \$200,000, were made in two categories: *Translational Research* awards--intended to move a company or company-university partnership to the next value inflection point; and *Commercialization* awards--focused on pushing a later stage product development to market entry. FY 2013 Award Recipients included: Adlyfe, Inc., Animalgesics, Inc., BioAssay, Cardiosolv, LLC, CrispTek LLC, NexImmune, Remedium, Opticul, BioAssay Works, and Sage Pharma.

As indicated in the summary of the Board's meetings, many of the companies that have received these awards have had the opportunity to present directly to the Board. In general, the Board has recognized the quality of the science and business they represent and supported the process by which they have been selected. The Board has recommended that the BioMaryland Center monitor the progress of the companies funded to develop a set of metrics tracking the impact of these awards on company growth and product commercialization.

Biotechnology Investment Incentive Tax Credit Program (BIITC)

The Biotechnology Investment Incentive Tax Credit Program (BIITC) has increased from its initial level of \$6 million to \$8 million three years ago, and this year was increased to \$10 million. It is one of the most successful programs administered by DBED. Now entering its eighth year, Maryland's BIITC remains the most competitive of its kind in the United States and serves as an exemplary model for angel investment incentives. This Program provides income tax credits equal to 50% of an eligible investment up to \$250,000 for investors in qualified seed and early stage Maryland biotechnology companies. To date, more than \$47 million in tax credits have been awarded, benefitting 62 companies Statewide and generating total investment of more than \$90 million in them.

The Board has repeatedly recognized the value of the BIITC program and supported the increases in funding proposed in the Governor's budget through testimony in Annapolis. In addition, the Board has recommended that the targeted companies for this program should be early stage and consistently has endorsed policies that encourage broader participation by more companies. Recommendations have specifically addressed annual and lifetime limits on the tax credits as well as administrative measures to increase the Program's efficiency.

InvestMaryland

InvestMaryland is an innovative program designed to vitalize venture capital funding in Maryland. This unique fund, approved by Maryland lawmakers during the 2011 Maryland General Assembly, is the largest venture capital investment initiative in the State's history. In March 2012, DBED raised the money for this fund through auctioning discounts to insurance companies for pre-paying their taxes. This was an extremely successful effort. The expected raise of \$70 million was exceeded, and \$84 million was actually raised. A portion of this money is funding the Maryland Venture Fund, and \$25 million was initially invested in three local venture capital firms for investment in Maryland life science, clean energy and technology companies. These firms are GroTech Ventures, New Atlantic Ventures, and Kinetic Ventures. The new fund's director and staff were hired, and the fund began operations in the fall of 2012.

InvestMaryland Challenge Business Competition

The Invest Maryland Challenge was a new Statewide business plan competition launched in FY 2013 recognizing top applicants in three categories – Life Sciences, Cyber/IT, and a general category. Over 200 applications were received, 55 of them from Life Sciences companies. The Life Sciences winner was Graybug, a Maryland company developing treatments for age-related macular degeneration, a prior recipient of the BioMaryland Center's translational research award.

In the original BioMaryland 2020 Strategic Plan, the Board envisioned the need for a robust venture fund to support companies throughout the growth continuum. However, the Board has also discussed the role of Government as "catalyst" rather than fulfilling all the requirements for a company's financing. The Maryland Venture Fund is a future source of later stage funding. Combined with investment from the private venture capital firms that received two thirds of InvestMaryland dollars, this represents a true public private partnership.

The Maryland Innovation Initiative

The Maryland Innovation Initiative (MII) Program, administered through TEDCO, was created to foster the transition of promising technologies (all) having significant commercial potential from qualifying research universities, where they were discovered, to the commercial sector, where they can be developed into products and services that meet identified market needs. Specifically, MII intends to foster the commercialization of such technologies through technology validation, market assessment, and the creation of start-up companies in Maryland based on a technologies from Johns Hopkins (all campuses), University of Maryland (UMB, UMCP, UBMC) and Morgan State University. This program also incentivizes collaborations among the different schools, departments, and institutions within and among the qualifying universities.

Awards of up to \$215,000, may be made for a project at a single Qualifying University (a “Sole Application”). A joint award may be made to two or more Qualifying Universities submitting a joint proposal and may total up to \$270,000.

In response to the observation that Maryland is ranked #2 in federal funding for R&D but below the 50th percentile on technology transfer and commercialization, this Program was initiated. The US Chamber of Commerce has cited it as one of the reasons it has recognized Maryland as #1 for Innovation two years in a row. MII is an example of a programmatic response to a perceived deficiency in the rate of commercialization raised in the BioMaryland 2020 Strategic Plan.

II. Ensuring Industry Growth and Competitiveness

BioMaryland Center: BioEntrepreneur Development Program

The BMC BioEntrepreneur Development Program provides a wide variety of services to bioscience entrepreneurs to help them establish and/or grow their businesses in Maryland. These include business plan counseling and resource support, identification of capital sources, access to regulatory expertise and intellectual property advice, location assistance, and training support for employees. One of the more popular BMC resources used by bioentrepreneurs is access to industry databases to support product development and marketing efforts. During the past two years, more than 200 company visits have generated thousands of searches on the databases at BMC’s Baltimore or Rockville offices to fortify their business plans. BMC spends approximately \$100,000 per year to make these databases available for companies. The value of the reports downloaded by companies averages more than \$3 million per year. To date, more than \$18M in reports has been downloaded by companies to support the marketing information in their business plans. Each company visit to the BMC’s offices for this database research also enables Center staff to connect directly with the bioentrepreneur and learn more about his or her company, share additional resource information, and identify other opportunities for BMC to assist with the company’s business growth. Currently the BioMaryland Center offers access to the following industry databases: BioMedTracker, Frost & Sullivan, MedTrack and Deloitte (now Thompson Reuters) Recap.

The BioMaryland Center routinely reports to the LSAB the results of company utilization of the databases, which are also reported through State Stat. Counseling and mentoring are one of the

primary functions of the BioMaryland Center which were originally outlined in the BioMaryland 2020 Strategic Plan.

III. Advancing Global Leadership Role/BioMaryland Branding

International Outreach

Each November, the State participates in MEDICA, the largest medical device conference in the world with more than 100,000 attendees. The State offers a booth for companies to exhibit, similar to BIO International and larger Maryland companies exhibit at their own booths. Collectively, more than 10 Maryland companies typically participate in this forum, often with ExportMD assistance.

The BIO 2013 meeting took place in April in Chicago. BioMaryland's presence featured a unique pavilion as venue for an unprecedented number of activities showcasing Maryland as a premier location for bioscience research and business growth. Once again, BMC and its partners helped the State to secure major visibility at this conference. The event drew more than 16,000 industry leaders from 49 states and 65 countries, with a record 25,000 + partnering meetings. New in the BioMaryland pavilion this year was a special series of discussions centered on the diagnosis, treatment and prevention of traumatic brain injury highlighting technologies, companies and locations from around the state. These presentations are available on the BMC website.

In addition to the BIO and MEDICA meetings, Maryland is growing its international presence in other ways as well. The BMC, in conjunction with the office of International Trade and the University of Maryland, has developed an ongoing relationship with Russia. Also, ongoing relationships in France provide unique opportunities for Maryland companies in oncology to interact with the Toulouse Cancer Cluster and in neurosciences with Medicen Paris Region.

Recognizing that biotechnology is ultimately a global business, the LSAB supports efforts to initiate outreach to other BioClusters. In addition, these relationships become a source of ideas for how other regions advance their life science industry. Maryland companies eventually need to penetrate markets outside the US and Maryland can attract companies from outside the US that need access to FDA.

Online Marketing and Branding: BioMaryland

The BioMaryland Center launched its new website shortly before BIO in April, 2013. The website provides an important link for current information about Maryland's biocompanies and the resources and partnership opportunities available to them. It also enables these companies and resources to be showcased not only locally, but also to those outside the State who may be thinking of starting a company, moving a company, or opening a U.S. headquarters or facility in Maryland. Visits to the BMC site have more than tripled, since the site launched in September 2009, to an average of more than 7,000 visitors per month. Since the site launched, it has received more than 147,000 visits from unique visitors from 152 countries. More than half of this traffic (68,000) has occurred during just 12 months. For the last two years, BMC has also been expanding its use of social media with Twitter, Facebook and Linked In, media the scientific community has been slower to adopt but whose uptake is increasing as its value is understood.

In the last year, the website has been substantially re-vamped to increase the accessibility of information to companies, especially for financing programs across the State: DBED, TEDCO, and MIPs information can also be easily found. The BioMaryland Directory of more than 500 companies has been printed as a handy booklet that has been the fastest moving piece of collateral produced by the BioMaryland Center. The LSAB has also encouraged and supported incorporating social media into its overall plan for “Marketing BioMaryland”.

BIO Maryland 2020 - Initial Implementation

For FY2014, the following programs were funded to support the life science sector.

FY 2014

- \$3.6 million: BioMaryland Center
- \$250,000: BioTechnical Institute
- \$10 million: Biotechnology Investment Incentive Tax Credit Program
- \$8 million: Research and Development Tax Credit Program
- \$1.2 million: Maryland Venture Fund
- \$10.4 million: Maryland Stem Cell Research Fund
- \$5 million: Maryland Innovation Initiative
- \$3.17 million: TEDCO Budget
- \$84 million Invest Maryland (March 2012); All Technologies/3 years

Summary

With the strategy set forth by the LSAB, and supported by the BioMaryland Center, the State is uniquely positioned to leverage its bioscience research, location and workforce assets, in a way that will continue to benefit not only Maryland residents but the global community. The LSAB advises BMC as it performs its vital roles as a central catalyst for the development and growth of Maryland’s bioscience industry, an important information portal, active industry advocate, and comprehensive resource provider. Maryland’s bioscience industry has a critical role feeding, fueling, and healing the world and makes recommendations consistent with achieving these goals. BMC’s support of the growth of this vibrant industry strengthens Maryland’s leadership role globally feeding, fueling, and healing the world while achieving the State’s economic development objectives.

Appendix A

2013 Life Sciences Advisory Board Members

Chair: Mr. H. Thomas Watkins, *CEO, Human Genome Sciences, Inc.*

Vice Chair: Ms. Rachel King, *Chief Executive Officer, GlycoMimetics, Inc.*

Standing: Mr. Dominick Murray, *Secretary, Maryland Department of Business and Economic Development (DBED)*

Mr. Rob Rosenbaum, *President and Executive Director, Maryland Technology Development Corporation (TEDCO)*

Appointed: Dr. Patrick G. O'Shea, *Interim Vice President for Research, University of Maryland, College Park*

Ms. Francesca Cook, *Vice President of Policy and Government Affairs, Pharmathene, Inc.*

Dr. Stephen Desiderio, *Director, Institute for Cell Engineering, Johns Hopkins School of Medicine*

Mr. David Iannucci, *Assistant Deputy Chief Administrative Officer, Prince George's County Government*

Dr. Nina Lamba, *President, CCL Biomedical, Inc.*

Mr. Peter Nitze, *President, DSM Nutritional Lipids*

Mr. Ted Olsen, *President, PathSensors, Inc.*

Dr. Jay A. Perman, M.D., *President, University of Maryland, Baltimore*

Dr. Hercules Pinkney, *President Emeritus, Montgomery College*

Dr. Mark Rohrbaugh, *Director, Office of Technology Transfer*

Mr. David W. Smith, *Business Director, Lonza Walkersville, Inc.*

Col. Andrea Stahl, Ph.D., *Deputy Commander, US Army Medical Research Institute of Infectious Diseases (USAMRIID)*

Mr. Ryan Sysko, *Founder and CEO, WellDoc, Inc.*

Vacant, *Director, Center for Drug Evaluation and Research, Food and Drug Administration*

Appendix B

Table 1: MD's 71,618 life sciences jobs are in the private sector, federal government and academic institutions – 3% of all jobs in Maryland

Maryland Life Sciences Jobs, Wages and Salaries			
Group	Jobs	Aggregate Wages & Salaries	Average Annual Salary
Private Sector	33,602	\$3,058,887,640	\$91,034
Federal Government	29,777	\$2,772,774,686	\$93,118
Academic	8,240	\$692,744,795	\$84,074
Total	71,618	\$6,524,407,122	\$91,100
Source: DBED analysis on data from the Maryland Department of Labor, Licensing and Regulation and Bureau of Labor Statistics. Published in <i>Life Sciences Maryland: the Jobs Analysis & Economic Impact Report 2011</i>			

Table 2: MD's private sector life sciences jobs are found largely in research, testing and medical laboratories

Maryland Private Life Sciences Jobs, Salaries and Facilities 2010				
Subsector	Employment		Facilities or Establishments	Average Annual Salary
	Jobs	Share		
Agricultural Feedstock and Chemicals	256	0.8%	22	\$63,780
Drugs and Pharmaceuticals	6,574	19.6%	65	\$102,084
Medical Devices and Equipment	1,962	5.8%	86	\$67,612
Research, Testing and Medical Laboratories	24,810	73.8%	1,579	\$90,239
Total	33,602	100%	1,752	\$91,034
Source: DBED analysis on data from the Maryland Department of Labor, Licensing and Regulation and Bureau of Labor Statistics. <i>Life Sciences Maryland: the Jobs Analysis & Economic Impact Report 2011</i>				

Appendix C– BIO 2020 Strategic Plan Funding: 2010-2014

Program	2010	2011	2012	2013	Total
Venture Capital Development					
Enterprise Investment Fund	0.95	0.55	0.48	7.85	9.83
InvestMaryland	0	0	0	14	14
MEDAAF	1.25	0.5	0	1.78	3.53
MIDFA	0	0.15	2.9	2.4	5.45
Maryland Incubator Support Fund	0.53	0.66	0.66	0.66	2.51
<i>Venture Capital Development Subtotal</i>	2.73	1.86	4.04	26.69	35.32
Tax Credits					
Maryland Biotech Investor Tax Credit Program	6	8	8	8	30
R&D Tax Credit Program	6	6	6	6	24
<i>Tax Credits Subtotal</i>	12	14	14	14	54
Research and Development					
Center for Biosystem Research - UMCP			1.7		1.7
Institute for Bioscience and Biotechnology Research (IBBR)- UMCP, UMB			6		6
Maryland Stem Cell Research Fund	12.35	10.4	12.4	10.4	45.55
Maryland Industrial Partnerships Program	2.9	4.2	1.2	1.5	9.8
Nanotechnology Investments	0.33	0	2.4		2.73
University of Maryland Biotechnology Institute	46.96				46.96
<i>Research and Development Subtotals</i>	62.54	14.6	23.7	11.9	112.74
Technology Transfer and Commercialization					
BioMaryland Center	4.69	3.79	3.63	3.51	15.62
Tech Transfer at USM			4.5	2	6.5
TEDCO Funding (includes technology transfer, commercialization funds, and MIPS)	3.39	3.46	3.27	3.17	13.29
Maryland Innovation Initiative				5	5
<i>Technology Transfer and Commercialization Subtotals</i>	8.08	7.25	11.4	13.68	40.41
Miscellaneous					
Partnership for Workforce Quality	0.49	0.07			0.56
Project Lead the Way			0.9		0.9
EARN ¹					0

Miscellaneous Subtotals	0.49	0.07	0.9	0	1.46
Programs Subtotal	85.84	37.78	54.04	66.27	243.93
Capital Projects					
Bowie State University	0	0	0	3.1	3.1
Cecil CC Sciences Lab	0	0	2.15	2	4.15
College of Notre Dame of MD New Pharmacy School	3.5	0	0	0	3.5
Coppin State University Science & Technology Center	9.75	6.5	0	28.78	45.03
Department of the Environment	0	0	0	24.76	24.76
Department of Health and Mental Hygiene	0	0	0	0.31	0.31
East Baltimore Biotechnology Park	5	5	2.5	5	17.5
Forensic Medical Center @ UMD BioPark	2.85	0	0	0	2.85
Frederick Community College Science/ Tech Hall	0	0.46	4.65	0.95	6.06
Greater Washington Life Sciences Fund	6	0	0	0	6
Howard CC Health Sciences Building	2	9.47	9.47	3.3	24.24
Howard CC Science, Engineering, and Technology Building	0	0	2.97	0	2.97
Kennedy Krieger Institute	0	0	1	1	2
Morgan State University	0	0	0	3.5	3.5
Montgomery College Rockville Science Center	1.01	4.24	6.21	1.16	12.62
Montgomery College/ Germantown Bioscience Education Center	16.1	16.1	0	1.86	34.06
Prince George's Community College Center for Health Studies	18.06	6.51	0	1.34	25.91
Sinai Hospital	0	0	0	1	1
University of Maryland Center for Environmental Sciences	0	0	0	1.2	1.2
UMB Health Sciences Research Facility	0	0	4.67	4.7	9.37
UMB School of Pharmacy	13.7	2.61	0	0	16.31
UBMC Center of Marine Biology	0	0	0.21	0	0.21
UMCES	0	0	0	1.15	1.15
UMCP Physical Sciences Complex	4.62	41.1	30.1	34.6	110.42
UMCP New Bioengineering Building	0	0	0	5	5
Capital Projects Subtotal	82.59	91.99	63.93	124.71	363.22
Totals	168.43	129.77	117.97	190.98	607.15

¹EARN program calculated with 25% of funds going towards Biotechnology

